Symbravo Tablet
Product Images NDC 81968-020

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Symbravo (NDC 81968-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Axsome Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

3-ct Sample Bottle Label (Bottle Label 3 Ct)

This text describes a medication containing 20 mg of meloxicam and 10 mg of rizatriptan, with additional details on storage conditions and dosage recommendations. It provides instructions on storage temperature, usage, and not using the product if the seal is broken. The information includes the NDC code, a note that it is for oral use, and a mention that it is a patient sample not for sale. It also includes details on dispensing the Medication Guide to each patient, manufacturing information, and a copyright notice with an expiry date and lot number.*

FDA Label Image

9-ct Bottle Label (Bottle Label 9 Ct)

Manufacturer: Axsome Therapeutics, Inc. New York, NY 10007. This product is a tablet called SYMBRA%O’, containing 20mg of meloxicam and 10mg of rizatriptan. Each tablet also includes 14.5mg of rizatriptan benzoate. It is recommended to dispense the medication guide to each patient. The storage instructions advise keeping the tablets in the original bottle at 20°C to 25°C (68°F to 77°F), with excursions allowed to 15°C to 30°C (59°F to 86°F). It is important not to use the product if the seal is broken. For dosage information, refer to the Prescribing Information.*

FDA Label Image

Figure 1 (Figure01)

This text appears to be a graph showing the percentage of pain relief over time after taking different medications. The medications shown are Rizatriptan, Meloxicam, and Placebo. The x-axis represents time in hours from dose, while the y-axis represents the percentage of pain relief.*

FDA Label Image

Figure 2 (Figure02)

This text shows a graph representing the percentage of individuals achieving freedom from Migraine-Associated Symptoms for different medications at various time intervals after the dose. The medications compared are MBS Freedom, Rizatriptan, Meloxicam, and Placebo. The graph indicates the effectiveness of each medication in providing relief from migraine symptoms over time.*

FDA Label Image

Figure 3 (Figure03)

This text shows a pain relief chart comparing a medication called SYMBRAVO to a placebo over time in hours from dosage. The chart displays the percentage of pain relief achieved by each medication.*

FDA Label Image

Figure 4 (Figure04)

This data shows the percentage of individuals achieving MBS Freedom over time in hours from dose. The chart displays the percentages from 0% to 100% at varying time intervals. It appears to compare the effectiveness of two different treatments, one marked as "—e—SYMBRAVO" and the other as "Placebo".*

FDA Label Image

3-ct Sample Carton Label (Sample Carton)

This text appears to be a description of a medication called Symbrayo, which is a tablet containing a combination of meloxicam and rizatriptan in the strengths of 20mg and 10mg respectively. Each bottle includes 3 tablets for oral use and is labeled as a patient sample, not for sale. It provides storage instructions, dosage information, and details on the manufacturer, Axsome Therapeutics, Inc. The medication guide should be dispensed along with the tablets.*

FDA Label Image

Structure (Structure01)

FDA Label Image

Structure (Structure02)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.